Milestone Pharmaceuticals, Inc. (MIST)
0.52
-0.14
(-20.63%)
USD |
NASDAQ |
Nov 13, 16:00
0.505
-0.02
(-2.88%)
After-Hours: 19:59
Milestone Pharmaceuticals Enterprise Value : 63.15M for Nov. 13, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2026 | 63.15M |
| November 12, 2026 | 79.98M |
| November 11, 2026 | 80.86M |
| November 10, 2026 | 80.86M |
| November 09, 2026 | 90.29M |
| November 06, 2026 | 93.38M |
| November 05, 2026 | 84.63M |
| November 04, 2026 | 94.59M |
| November 03, 2026 | 92.94M |
| November 02, 2026 | 88.19M |
| October 30, 2026 | 89.30M |
| October 29, 2026 | 96.72M |
| October 28, 2026 | 92.71M |
| October 27, 2026 | 84.47M |
| October 26, 2026 | 78.64M |
| October 23, 2026 | 79.11M |
| October 22, 2026 | 85.90M |
| October 21, 2026 | 84.98M |
| October 20, 2026 | 87.86M |
| October 19, 2026 | 85.57M |
| October 16, 2026 | 86.47M |
| October 15, 2026 | 97.33M |
| October 14, 2026 | 96.50M |
| October 13, 2026 | 93.75M |
| October 12, 2026 | 98.70M |
| Date | Value |
|---|---|
| October 09, 2026 | 93.65M |
| October 08, 2026 | 87.07M |
| October 07, 2026 | 92.68M |
| October 06, 2026 | 93.55M |
| October 05, 2026 | 95.45M |
| October 02, 2026 | 99.22M |
| October 01, 2026 | 99.97M |
| September 30, 2026 | 106.19M |
| September 29, 2026 | 73.31M |
| September 28, 2026 | 70.25M |
| September 25, 2026 | 69.38M |
| September 24, 2026 | 70.19M |
| September 23, 2026 | 78.54M |
| September 22, 2026 | 85.89M |
| September 21, 2026 | 85.49M |
| September 18, 2026 | 85.24M |
| September 17, 2026 | 85.71M |
| September 16, 2026 | 81.93M |
| September 15, 2026 | 86.72M |
| September 14, 2026 | 89.42M |
| September 11, 2026 | 93.24M |
| September 10, 2026 | 101.95M |
| September 09, 2026 | 104.44M |
| September 08, 2026 | 111.28M |
| September 04, 2026 | 120.62M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| NervGen Pharma Corp. | 138.88M |
| Appili Therapeutics, Inc. | 9.586M |
| Clearmind Medicine, Inc. | -12.92M |
| Lexaria Bioscience Corp. | 3.413M |
| Target Group, Inc. (Canada) | 11.72M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -25.80M |
| Revenue (Quarterly) | 2.963M |
| Total Expenses (Quarterly) | 28.76M |
| EPS Diluted (Quarterly) | -0.1831 |
| Gross Profit Margin (Quarterly) | 87.11% |
| Profit Margin (Quarterly) | -870.6% |
| Earnings Yield | -144.9% |
| Normalized Earnings Yield | -144.87 |